Prediction parameters for radiation pneumonitis in patients with stage III NSCLC.

Pérez, E. García; Peloche, Maria Guadalupe Bermudo; Quiroz, Christian Fernando Arias; García, Yolanda; Portulas, Elsa Dalmau; Monné, J; Astudillo, Arnaldo Alvarado; Torne, Manuel Lujan

doi:10.1200/jco.2014.32.15_suppl.e18538

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, the odds ratio for patients receiving radiation therapy in combination with MTA or CA was 11.39 (95% CI; 3.408–38.076). A previous study of advanced lung cancer showed that 87% of participants treated with conventional chemoradiation therapy experienced complicated pneumonitis at any grade . This phenomenon is attributable to radiotherapy being directly toxic to parenchymal lung cells and inducing the inflammatory process, which was exacerbated by drug therapy .…”

Section: Discussionmentioning

confidence: 99%

“…A previous study of advanced lung cancer showed that 87% of participants treated with conventional chemoradiation therapy experienced complicated pneumonitis at any grade. (8) This phenomenon is attributable to radiotherapy being directly toxic to parenchymal lung cells and inducing the inflammatory process, which was exacerbated by drug therapy. (7) In addition, it is well known that increases in drug dose and combinations of different drugs increase the incidence of DILD.…”

Section: Discussionmentioning

confidence: 99%

“…(7) In addition, it is well known that increases in drug dose and combinations of different drugs increase the incidence of DILD. (8) Thus, special caution is needed for patients with low BSA in addition to the abovementioned risk factors who are receiving combination therapy.…”

Section: Discussionmentioning

confidence: 99%

“…This phenomenon is attributable to radiotherapy being directly toxic to parenchymal lung cells and inducing the inflammatory process, which was exacerbated by drug therapy . In addition, it is well known that increases in drug dose and combinations of different drugs increase the incidence of DILD . Thus, special caution is needed for patients with low BSA in addition to the abovementioned risk factors who are receiving combination therapy.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Drug induced interstitial lung disease in oncology phase I trials

Yonemori

Hirakawa

Kawachi³

et al. 2016

Cancer Science

View full text Add to dashboard Cite

Interstitial lung disease is a serious drug‐related condition that can cause life threatening organ failure. The incidence and risk factors of drug‐induced interstitial lung disease (DILD) are unknown in oncology phase I trials. This study analyzed clinical information from 8906 patients with malignancies who were enrolled in 470 phase I trials sponsored by the Cancer Therapy Evaluation Program, National Cancer Institute, from 1988 to 2014. Logistic and Cox statistical analyses were utilized to determine clinical differences between patients who developed DILD and patients who did not. In this study, the overall incidence rate of patients with pulmonary toxicity was 2.7%. The overall incidence rate for DILD was 0.77%, whereas for grade 3 or 4 DILD it was 0.31%. Median time to occurrence of DILD was 1.4 months. The Cox hazard analysis indicated smaller body surface area and a combination of thoracic radiation with investigational drug regimens were significant risk factors for time to occurrence of interstitial lung disease. Investigators should carefully monitor for DILD in oncology patients enrolled in phase I trials with identified risk factors. A 6‐month observation period would be sufficient to detect the onset of most DILD in such patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Drug induced interstitial lung disease in oncology phase I trials

Yonemori

Hirakawa

Kawachi³

et al. 2016

Cancer Science

View full text Add to dashboard Cite

show abstract

Cancer therapy-related interstitial lung disease

Zhou,

Deng,

Yang

et al. 2024

Chinese Medical Journal

View full text Add to dashboard Cite

With the increasing utilization of cancer therapy, the incidence of lung injury associated with these treatments continues to rise. The recognition of pulmonary toxicity related to cancer therapy has become increasingly critical, for which interstitial lung disease (ILD) is a common cause of mortality. Cancer therapy-related ILD (CT-ILD) can result from a variety of treatments including chemotherapy, targeted therapy, immune checkpoint inhibitors, antibody–drug conjugates, and radiotherapy. CT-ILD may progress rapidly and even be life-threatening; therefore, prompt diagnosis and timely treatment are crucial for effective management. This review aims to provide valuable information on the risk factors associated with CT-ILD; elucidate its underlying mechanisms; discuss its clinical features, imaging, and histological manifestations; and emphasize the clinical-related views of its diagnosis. In addition, this review provides an overview of grading, typing, and staging treatment strategies used for the management of CT-ILD.

show abstract

Prediction parameters for radiation pneumonitis in patients with stage III NSCLC.

Cited by 2 publications

References 0 publications

Drug induced interstitial lung disease in oncology phase I trials

Drug induced interstitial lung disease in oncology phase I trials

Cancer therapy-related interstitial lung disease

Contact Info

Product

Resources

About